Name : FITC-Labeled Human VEGF165 Protein
Product Source :
Recombinant FITC-Labeled Human VEGF165 Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Ala27-Arg191.[Accession | P15692-4]
Molecular Weight :
The protein has a predicted MW of 22.2 kDa. Due to glycosylation, the protein migrates to 28-33 kDa under reduced (R) condition, 45-55 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE FITC-Labeled Human VEGF165 on Tris-Bis PAGE under reduced (R) condition and Non reducing (N) condition. The purity is greater than 95%. SEC-HPLC The purity of FITC-Labeled Human VEGF165 is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized FITC-Labeled Human VEGF165, His Tag at 0.2μg/ml (100μl/well) on the plate. Dose response curve for Anti-VEGF165 Antibody, hFc Tag with the EC50 of 22.3ng/ml determined by ELISA.
Background :
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189.
Synonyms :
VEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609;VEGF-165
References & Citations :
(1)Rosen, L. S. VEGF-Targeted Therapy: Therapeutic Potential and Recent Advances[J]. The Oncologist, 2005, 10(6):382-391.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
PCSK9 ProteinGene ID
DAP10 Proteincustom synthesis
Popular categories:
Carbonic Anhydrase 14 (CA-XIV)
Tissue Inhibitor of Metalloproteinase 4 (TIMP-4)